Cellular reprogramming (e.g., iPSC generation) underpins regenerative medicine. Early integration of viral vectors carried oncogenic risks via genomic alteration. Creative Biolabs' Custom mRNA-based Cell Reprogramming Services offer non-integrating, footprint-free solutions using modified/saRNA, ensuring safety and efficiency.
The service accelerates clinical-grade cell product development, eliminating insertional mutagenesis risks. With precise, scalable technologies, it supports research-to-clinical transition, enabling high-quality cell lines for regenerative medicine and next-gen immunotherapy.
Discover How We Can Help - Request a Consultation
Creative Biolabs offers specialized mRNA services tailored to diverse therapeutic applications, ensuring that your starting material is optimally converted or modified for its final clinical purpose.
| T Cell Reprogramming by mRNA | Dendritic Cell Reprogramming by mRNA |
| High-efficiency, non-viral delivery of synthetic mRNA for the transient or stable expression of chimeric antigen receptors (CARs) or other engineering factors in primary T cells. This allows for rapid, scalable production of next-generation CAR-T therapies while maintaining high cell viability and avoiding the permanent integration risks associated with viral delivery. | Utilizing customized mRNA to load antigens or modulate the expression of transcription factors and cytokines within dendritic cells. This is a powerful tool for developing personalized cancer vaccines and optimizing the antigen-presenting function of the cells ex vivo or in vivo. |
| Natural Killer Cell Reprogramming by mRNA | B Cell Reprogramming by mRNA |
| Specialized protocols for transfecting sensitive Natural Killer (NK) cells with synthetic mRNA encoding activating receptors (e.g., CCR7, CD16) or CARs. Our method ensures rapid transgene expression, high viability, and preserves the intrinsic cytotoxic function of NK cells for allogeneic immunotherapy. | Leveraging mRNA to induce pluripotency in B cells or to modify their function. This often involves factor cocktails (e.g., Yamanaka factors OSKM) to dedifferentiate early-stage B cells, or supplementary factors to modify mature B cells for research into antibody production and immunological memory. |
| iPSC Reprogramming by mRNA | |
| The core service for regenerative medicine. We deliver optimized cocktails of modified mRNA encoding transcription factors (OCT4, SOX2, KLF4, cMYC, etc.) into somatic cells. This guarantees the generation of high-quality, clinical-grade iPSC lines with superior efficiency and no genomic footprint, ready for differentiation into complex cell types like neurons or cardiomyocytes. |
The typical process is designed to be clear, iterative, and optimized for speed and quality control.
Finalize reprogramming strategy (modified mRNA/saRNA choice) and optimal non-viral delivery system (e.g., LNP, electroporation) for client’s source cells.
Synthesize high-quality capped/polyadenylated mRNA with proprietary nucleoside modifications (e.g., Pseudouridine, 5-Methylcytidine) to boost stability and silence innate immunity.
Apply optimized daily/single-shot transfection, manage specialized media and low-oxygen culture conditions to maximize reprogramming efficiency and colony formation.
Mechanically isolate high-quality, morphologically correct colonies; expand under feeder-free, defined conditions to generate a master cell bank.
Conduct comprehensive analysis (karyotyping, pluripotency/marker flow cytometry, integration-free PCR).
The typical timeframe for iPSC generation and characterization using our service ranges from 8 to 14 weeks, depending on the complexity of the starting cell type and the scope of the required Quality Control assays.
Our Custom mRNA based Cell Reprogramming Services platform, provided by Creative Biolabs, delivers unparalleled control and quality in non-viral cell engineering:
Footprint-Free Technology Guarantee
Use non-integrating modified mRNA for cell lines (iPSCs, modified T/NK cells) to eliminate residual vector traces and insertional mutagenesis risk for clinical translation.
Nucleoside Modification Expertise
Custom synthesize and incorporate proprietary nucleoside analogs (e.g., Pseudouridine, 5-Methylcytidine) to enhance mRNA stability, translation efficiency, and reduce innate immune response.
Flexible Reprogramming Mode Selection
Offer tailored strategies: high-yield stabilized modified mRNA (daily dosing) or saRNA (single-shot reprogramming) to cut hands-on time and accelerate timelines.
Custom Cell Type and Factor Cocktails
Provide specialized protocols for diverse source cells (T/B/NK cells, Dendritic cells, Fibroblasts) with adjustable factor stoichiometry (e.g., OSKM ratios) for project-specific needs.
Optimized Non-Viral Delivery Solutions
Support selection and optimization of efficient, non-toxic delivery systems (custom LNP formulations, electroporation parameter fine-tuning) for specific cell types.
Scalability for Industrialization
Enable seamless small-to-large-scale production transition with standardized, cGMP-compatible materials/processes for late-stage development consistency.
Some studies have used synthetic RNA to prepare iPS cells from PBMCs. Although the methods and frequencies of RNA transfection have been optimized for PBMCs. Approximately 14 days after the initial RNA transfection, iPS cell-like colonies of sufficient size emerged, and MDM4 mRNA significantly enhanced the efficiency of PBMCs reprogramming. iPS cell clones established using synthetic RNA from PBMCs exhibit normal colony morphology and karyotype, and their gene expression is similar to that of mature iPS cell lines. Immunostaining showed that PAX6, KRT12, and p63 were co-expressed and successfully differentiated into corneal epithelioid cells.
Fig.1 IPSCs were generated from PBMC using mRNA synthesized in vitro.1
Experience the Creative Biolabs Advantage - Get a Quote Today
While both are non-integrating, mRNA is inherently safer because it never enters the cell nucleus and is rapidly degraded in the cytoplasm, guaranteeing a true "footprint-free" status. Episomal vectors are DNA-based and, while designed not to integrate, still carry a low but detectable risk of genomic recombination, requiring more intensive, costly screening to confirm their clearance.
Creative Biolabs addresses this in two ways: first, our nucleoside-modified mRNA is far more stable and efficiently translated than standard RNA, maximizing protein output per transfection. Second, we offer specialized Self-Amplifying RNA (saRNA), which self-replicates in the cytoplasm, achieving a sustained, high-level expression burst from a single delivery, dramatically boosting efficiency.
Absolutely. Our platform is ideal for allogeneic approaches. We can leverage mRNA-delivered gene-editing components to conduct targeted HLA gene editing on cell lines during the reprogramming or modification phase. This creates "universal donor" cell lines by reducing immunogenicity, which is essential for mass-market, off-the-shelf therapeutic development.
Our protocols are highly versatile and optimized for a wide range of clinically relevant starting cells, including T cells, B cells, Dendritic cells, Fibroblasts, and PBMCs. We tailor the delivery mechanism (e.g., LNP formulation or electroporation parameters) to ensure maximum viability and efficiency for your specific source material.
Our service significantly reduces industrial complexity. The use of saRNA reduces labor (fewer transfections), while our high-efficiency protocols increase yield, lowering the cost per clinical-grade cell line. Furthermore, we provide standardized, cGMP-compatible synthetic mRNA, ensuring consistency and easier regulatory compliance for large-scale manufacturing.
Creative Biolabs is dedicated to accelerating your transition from scientific discovery to a safe, scalable, and functionally superior cell therapy product. Our Custom mRNA based Cell Reprogramming Services are the definitive solution for achieving footprint-free genomic safety and industrial-grade efficiency.
Contact Our Team for More Information and to Discuss Your Project
Reference
